Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)14, (Arg/Lys)15]nociceptin on ORL1 receptor binding and activation

Hirokazu Nishimura, Jinglan Li, Kaname Isozaki, Kazushi Okada, Ayami Matsushima, Takeru Nose, Tommaso Costa, Yasuyuki Shimohigashi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

ORL1 is an endogenous G protein-coupled receptor for neuropeptide nociceptin. [(R/K)14, (R/K)15]nociceptin is a superagonist that strongly activates the ORL1 receptor. We have previously found that substituting with Trp can reproduce the potentiation induced by Arg or Lys at position 14. In the present study, in order to ensure the effect of Trp-substitution on the activities of [(R/K)14, (R/K)15]nociceptin, we synthesized [W14, (R/K)15]nociceptin and [(R/K)14, W15]nociceptin. [W14, (R/K)15]nociceptin was found to exhibit threefold higher binding activity and 10-fold greater potency in a functional [35S]GTPγS functional assay as compared to wild-type nociceptin. However, when only Trp was placed in position 15, the resulting analogues, [(R/K)14, W15]nociceptin, showed only a moderate enhancement of binding and biological activity (2-3 fold in both). These results indicate that the placement of Trp at position 14, unlike at position 15, enhances in a synergistic fashion the interaction of nociceptin with the ORL1 receptor. The results indicate that specific interactions feasible for Arg/Lys and Trp in common must be there for aromatic residues in ORL1, thus forming a cation/π interaction or π/π hydrophobic interaction. The necessity for a favorable electrostatic interaction appears strict in position 15.

Original languageEnglish
Pages (from-to)5683-5687
Number of pages5
JournalBioorganic and Medicinal Chemistry
Volume17
Issue number15
DOIs
Publication statusPublished - Aug 1 2009

Fingerprint

Substitution reactions
Chemical activation
nociceptin
nociceptin receptor
Arg(14)-Lys(15)-nociceptin
G-Protein-Coupled Receptors
Coulomb interactions
Bioactivity
Neuropeptides
Static Electricity
Hydrophobic and Hydrophilic Interactions
Cations
Assays

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)14, (Arg/Lys)15]nociceptin on ORL1 receptor binding and activation. / Nishimura, Hirokazu; Li, Jinglan; Isozaki, Kaname; Okada, Kazushi; Matsushima, Ayami; Nose, Takeru; Costa, Tommaso; Shimohigashi, Yasuyuki.

In: Bioorganic and Medicinal Chemistry, Vol. 17, No. 15, 01.08.2009, p. 5683-5687.

Research output: Contribution to journalArticle

Nishimura, Hirokazu ; Li, Jinglan ; Isozaki, Kaname ; Okada, Kazushi ; Matsushima, Ayami ; Nose, Takeru ; Costa, Tommaso ; Shimohigashi, Yasuyuki. / Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)14, (Arg/Lys)15]nociceptin on ORL1 receptor binding and activation. In: Bioorganic and Medicinal Chemistry. 2009 ; Vol. 17, No. 15. pp. 5683-5687.
@article{ae2b84bc3f114ae09b16f481dc2ff8cc,
title = "Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)14, (Arg/Lys)15]nociceptin on ORL1 receptor binding and activation",
abstract = "ORL1 is an endogenous G protein-coupled receptor for neuropeptide nociceptin. [(R/K)14, (R/K)15]nociceptin is a superagonist that strongly activates the ORL1 receptor. We have previously found that substituting with Trp can reproduce the potentiation induced by Arg or Lys at position 14. In the present study, in order to ensure the effect of Trp-substitution on the activities of [(R/K)14, (R/K)15]nociceptin, we synthesized [W14, (R/K)15]nociceptin and [(R/K)14, W15]nociceptin. [W14, (R/K)15]nociceptin was found to exhibit threefold higher binding activity and 10-fold greater potency in a functional [35S]GTPγS functional assay as compared to wild-type nociceptin. However, when only Trp was placed in position 15, the resulting analogues, [(R/K)14, W15]nociceptin, showed only a moderate enhancement of binding and biological activity (2-3 fold in both). These results indicate that the placement of Trp at position 14, unlike at position 15, enhances in a synergistic fashion the interaction of nociceptin with the ORL1 receptor. The results indicate that specific interactions feasible for Arg/Lys and Trp in common must be there for aromatic residues in ORL1, thus forming a cation/π interaction or π/π hydrophobic interaction. The necessity for a favorable electrostatic interaction appears strict in position 15.",
author = "Hirokazu Nishimura and Jinglan Li and Kaname Isozaki and Kazushi Okada and Ayami Matsushima and Takeru Nose and Tommaso Costa and Yasuyuki Shimohigashi",
year = "2009",
month = "8",
day = "1",
doi = "10.1016/j.bmc.2009.06.015",
language = "English",
volume = "17",
pages = "5683--5687",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "15",

}

TY - JOUR

T1 - Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)14, (Arg/Lys)15]nociceptin on ORL1 receptor binding and activation

AU - Nishimura, Hirokazu

AU - Li, Jinglan

AU - Isozaki, Kaname

AU - Okada, Kazushi

AU - Matsushima, Ayami

AU - Nose, Takeru

AU - Costa, Tommaso

AU - Shimohigashi, Yasuyuki

PY - 2009/8/1

Y1 - 2009/8/1

N2 - ORL1 is an endogenous G protein-coupled receptor for neuropeptide nociceptin. [(R/K)14, (R/K)15]nociceptin is a superagonist that strongly activates the ORL1 receptor. We have previously found that substituting with Trp can reproduce the potentiation induced by Arg or Lys at position 14. In the present study, in order to ensure the effect of Trp-substitution on the activities of [(R/K)14, (R/K)15]nociceptin, we synthesized [W14, (R/K)15]nociceptin and [(R/K)14, W15]nociceptin. [W14, (R/K)15]nociceptin was found to exhibit threefold higher binding activity and 10-fold greater potency in a functional [35S]GTPγS functional assay as compared to wild-type nociceptin. However, when only Trp was placed in position 15, the resulting analogues, [(R/K)14, W15]nociceptin, showed only a moderate enhancement of binding and biological activity (2-3 fold in both). These results indicate that the placement of Trp at position 14, unlike at position 15, enhances in a synergistic fashion the interaction of nociceptin with the ORL1 receptor. The results indicate that specific interactions feasible for Arg/Lys and Trp in common must be there for aromatic residues in ORL1, thus forming a cation/π interaction or π/π hydrophobic interaction. The necessity for a favorable electrostatic interaction appears strict in position 15.

AB - ORL1 is an endogenous G protein-coupled receptor for neuropeptide nociceptin. [(R/K)14, (R/K)15]nociceptin is a superagonist that strongly activates the ORL1 receptor. We have previously found that substituting with Trp can reproduce the potentiation induced by Arg or Lys at position 14. In the present study, in order to ensure the effect of Trp-substitution on the activities of [(R/K)14, (R/K)15]nociceptin, we synthesized [W14, (R/K)15]nociceptin and [(R/K)14, W15]nociceptin. [W14, (R/K)15]nociceptin was found to exhibit threefold higher binding activity and 10-fold greater potency in a functional [35S]GTPγS functional assay as compared to wild-type nociceptin. However, when only Trp was placed in position 15, the resulting analogues, [(R/K)14, W15]nociceptin, showed only a moderate enhancement of binding and biological activity (2-3 fold in both). These results indicate that the placement of Trp at position 14, unlike at position 15, enhances in a synergistic fashion the interaction of nociceptin with the ORL1 receptor. The results indicate that specific interactions feasible for Arg/Lys and Trp in common must be there for aromatic residues in ORL1, thus forming a cation/π interaction or π/π hydrophobic interaction. The necessity for a favorable electrostatic interaction appears strict in position 15.

UR - http://www.scopus.com/inward/record.url?scp=67651114032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651114032&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2009.06.015

DO - 10.1016/j.bmc.2009.06.015

M3 - Article

VL - 17

SP - 5683

EP - 5687

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 15

ER -